Oncolytics Biotech (ONCY) Total Current Liabilities (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Total Current Liabilities of $6.1 million for Q4 2025, up 27.45% year-over-year from $4.8 million in Q4 2024, and up 9.68% quarter-over-quarter from $5.6 million in Q3 2025.
Oncolytics Biotech (ONCY) Total Current Liabilities (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Total Current Liabilities for 17 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 27.45% year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $6.1 million (up 27.45% YoY), while the FY2025 annual figure was $6.1 million, up 24.89% from the prior year.
- Total Current Liabilities rose to $6.1 million in Q4 2025 per ONCY's latest filing, from $5.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $7.5 million in Q3 2023 and bottomed at $1.8 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.0 million in 2022.
- Annual changes were most pronounced in 2021 — Total Current Liabilities tumbled 55.71% — and 2023, when it surged 165.84%.
- Oncolytics Biotech's Total Current Liabilities stood at $2.1 million in 2021, then jumped by 36.19% to $2.9 million in 2022, then rose by 7.09% to $3.1 million in 2023, then jumped by 53.81% to $4.8 million in 2024, then advanced by 27.45% to $6.1 million in 2025.
- Business Quant data shows ONCY's Total Current Liabilities at $6.1 million in Q4 2025, $5.6 million in Q3 2025, and $4.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | Oncolytics Biotech | 100.61 Mn | 100.61 Mn | - | 5.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.23 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Jun 30, 2025 | 4.73 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 5.62 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 3.11 Mn |
| Sep 30, 2023 | 7.47 Mn |
| Jun 30, 2023 | 1.97 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 2.81 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 2.13 Mn |
| Sep 30, 2021 | 2.15 Mn |
| Jun 30, 2021 | 2.10 Mn |